M. Wilusz

C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.

F. Dumont, G. Wiederrecht, M. Wyvratt, 1998, Bioorganic & medicinal chemistry letters.

High anti tumor activity against rhabdomyosarcoma cells and low normal cells cytotoxicity of heat shock protein 90 inhibitors, with special emphasis on 17-[2-(pyrrolidin-1-yl)ethyl]-aminno-17-demethoxygeldanamycin.

M. Majka, J. Gozdzik, K. Miekus, 2009, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus.

N. Sigal, S. O'keefe, M. Martin, 1998, Transplantation.

Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?

J. Todd, P. Lyons, C. Lord, 2000, Cytokine.

Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity.

F. Dumont, G. Wiederrecht, M. Wyvratt, 1999, Bioorganic & medicinal chemistry letters.

C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.

F. Dumont, G. Wiederrecht, M. Wyvratt, 1998, Bioorganic & medicinal chemistry letters.

Inhibition of rhabdomyosarcoma's metastatic behavior through downregulation of MET receptor signaling.

M. Majka, K. Miekus, G. Drabik, 2010, Folia histochemica et cytobiologica.

Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping.

J. Todd, P. Lyons, P. Denny, 2000, Genome research.

Role of the Wnt/β-catenin network in regulating hematopoiesis

M. Majka, M. Wilusz, 2008, Archivum Immunologiae et Therapiae Experimentalis.